Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Probiotics | Research

Investigation of the anti-inflammatory effects of native potential probiotics as supplementary therapeutic agents in an in-vitro model of inflammation

Authors: Shadi Aghamohammad, Amin Sepehr, Seyedeh Tina Miri, Saeideh Najafi, Mohammad R. Pourshafie, Mahdi Rohani

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Background

IBD is considered an inflammatory disease with abnormal and exaggerated immune responses. To control the symptoms, different theraputic agents could be used, however, utilizing the agents with the least side effects could be important. Probiotics as beneficial microorganisms are one of the complementory theraputic agents that could be used to modulate inflammatory signaling pathways. In the current study, we aimed to identify the precise molecular effects of potential probiotics on signaling pathways involved in the development of inflammation.

Methods

A quantitative real-time polymerase chain reaction (qPCR) assay was used to analyze the expression of JAK /STAT (JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, STAT4, STAT5 and STAT6) and inflammatory genes (NEMO, TIRAP, IRAK, and RIP) after the HT -29 cell line treatment with the sonicated pathogens and potential probiotics. A cytokine assay was also used to evaluate IL -6 and IL -1β production after potential probiotic treatment.

Results

The potential probiotic cocktail downregulated the JAK genes and TIRAP, IRAK4, NEMO, and RIP genes in the NF-kB pathway compared with cells that were treated with sonicated gram negative pathogens. The expression of STAT genes was different after potential probiotic treatment. The production of IL -6 and IL -1β decreased after potential probiotic treatment.

Conclusions

Considering the importance of controlling the symptoms of IBD to improve the life quality of the patients, using probiotic could be crucial. In the current study the studied native potential probiotic cocktails showed anti-inflammatory effects via modulation of JAK /STAT and NF-kB signaling pathways. This observation suggests that our native potential probiotics consumption could be useful in reducing intestinal inflammation.
Literature
1.
Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Reviews Gastroenterol Hepatol. 2019;16(9):531–43.CrossRef
2.
Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.CrossRef
3.
Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020;510:556–65.CrossRefPubMedPubMedCentral
4.
Singh S, Kullo IJ, Pardi DS, Loftus EV. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Reviews Gastroenterol Hepatol. 2015;12(1):26–35.CrossRef
5.
Bernstein CN. Treatment of IBD: where we are and where we are going. Official J Am Coll Gastroenterology| ACG. 2015;110(1):114–26.CrossRef
6.
Dejban P, Nikravangolsefid N, Chamanara M, Dehpour A, Rashidian A. The role of medicinal products in the treatment of inflammatory bowel diseases (IBD) through inhibition of TLR4/NF-kappaB pathway. Phytother Res. 2021;35(2):835–45.CrossRefPubMed
7.
Vidya MK, Kumar VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like receptors: significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol. 2018;37(1):20–36.CrossRefPubMed
8.
Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Reviews Gastroenterol Hepatol. 2020;17(6):323–37.CrossRef
9.
Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterology: WJG. 2015;21(19):5985.CrossRefPubMedCentral
10.
Bjarnason I, Sission G. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology. 2019;27(3):465–73.CrossRefPubMedPubMedCentral
11.
Liu M, Ding J, Zhang H, Shen J, Hao Y, Zhang X, et al. Lactobacillus casei LH23 modulates the immune response and ameliorates DSS-induced colitis via suppressing JNK/p-38 signal pathways and enhancing histone H3K9 acetylation. Food Funct. 2020;11(6):5473–85.CrossRefPubMed
12.
Leccese G, Bibi A, Mazza S, Facciotti F, Caprioli F, Landini P, et al. Probiotic Lactobacillus and Bifidobacterium strains counteract adherent-invasive Escherichia coli (AIEC) virulence and hamper IL-23/Th17 axis in ulcerative colitis, but not in crohn’s disease. Cells. 2020;9(8):1824.CrossRefPubMedPubMedCentral
13.
Rohani M, Noohi N, Talebi M, Katouli M, Pourshafie MR. Highly heterogeneous probiotic Lactobacillus species in healthy Iranians with low functional activities. PLoS ONE. 2015;10(12):e0144467.CrossRefPubMedPubMedCentral
14.
Eshaghi M, Bibalan MH, Rohani M, Esghaei M, Douraghi M, Talebi M, et al. Bifidobacterium obtained from mother’s milk and their infant stool; a comparative genotyping and antibacterial analysis. Microb Pathog. 2017;111:94–8.CrossRefPubMed
15.
Aghamohammad S, Sepehr A, Miri ST, Najafi S, Rohani M, Pourshafiea MR. The effects of the probiotic cocktail on modulation of the NF-kB and JAK/STAT signaling pathways involved in the inflammatory response in bowel disease model. BMC Immunol. 2022;23(1):1–10.CrossRef
16.
Ghanavati R, Asadollahi P, Shapourabadi MB, Razavi S, Talebi M, Rohani M. Inhibitory effects of Lactobacilli cocktail on HT-29 colon carcinoma cells growth and modulation of the Notch and Wnt/β-catenin signaling pathways. Microb Pathog. 2020;139:103829.CrossRefPubMed
17.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101–8.CrossRefPubMed
18.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Reviews Gastroenterol Hepatol. 2015;12(12):720–7.CrossRef
19.
Chibbar R, Dieleman LA. Probiotics in the management of ulcerative colitis. J Clin Gastroenterol. 2015;49:50–S5.CrossRef
20.
Guo W, Mao B, Cui S, Tang X, Zhang Q, Zhao J, et al. Protective effects of a novel probiotic Bifidobacterium pseudolongum on the intestinal barrier of colitis mice via modulating the Pparγ/STAT3 pathway and intestinal microbiota. Foods. 2022;11(11):1551.CrossRefPubMedPubMedCentral
21.
Wu F, Wuri G, Fang B, Shi M, Zhang M, Zhao L. Alleviative mechanism and effect of Bifidobacterium animalis A6 on dextran sodium sulfate-induced ulcerative colitis in mice. Food Sci Nutr. 2023;11(2):892–902.CrossRefPubMed
22.
Cordes F, Foell D, Ding JN, Varga G, Bettenworth D. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease. World J Gastroenterol. 2020;26(28):4055.CrossRefPubMedPubMedCentral
23.
Mehta DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL‐21 receptor. Immunol Rev. 2004;202(1):84–95.CrossRefPubMed
24.
Parmigiani A, Lichtenheld M, Pahwa S. IL-21 reduces production of pro-inflammatory cytokines by activated CD8 T cells (44.26). Am Assoc Immnol; 2012.
25.
Connelly TM, Koltun WA, Berg AS, Hegarty JP, Brinton D, Deiling S, et al. A single nucleotide polymorphism in the STAT5 gene favors colonic as opposed to small-bowel inflammation in Crohn’s disease. Dis colon rectum. 2013;56(9):1068–74.CrossRefPubMed
26.
Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line: pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277(37):33676–82.CrossRefPubMed
27.
Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol. 2009;9(4):447–53.CrossRefPubMedPubMedCentral
28.
Zundler S, Neurath MF. Integrating immunologic signaling networks: the JAK/STAT pathway in colitis and colitis-associated cancer. Vaccines. 2016;4(1):5.CrossRefPubMedPubMedCentral
29.
Delgado-Ramirez Y, Ocaña-Soriano A, Ledesma-Soto Y, Olguín JE, Hernandez-Ruiz J, Terrazas LI, et al. STAT6 is critical for the induction of Regulatory T cells in vivo Controlling the initial steps of Colitis-Associated Cancer. Int J Mol Sci. 2021;22(8):4049.CrossRefPubMedPubMedCentral
30.
31.
Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13(7):693–703.CrossRefPubMed
32.
Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15.CrossRef
33.
Gao K, Wang C, Liu L, Dou X, Liu J, Yuan L, et al. Immunomodulation and signaling mechanism of Lactobacillus rhamnosus GG and its components on porcine intestinal epithelial cells stimulated by lipopolysaccharide. J Microbiol Immunol Infect. 2017;50(5):700–13.CrossRefPubMed
34.
Lutz C, Weder B, Hünerwadel A, Fagagnini S, Lang B, Beerenwinkel N, et al. Myeloid differentiation primary response gene (MyD) 88 signalling is not essential for intestinal fibrosis development. Sci Rep. 2017;7(1):1–10.CrossRef
Metadata
Title
Investigation of the anti-inflammatory effects of native potential probiotics as supplementary therapeutic agents in an in-vitro model of inflammation
Authors
Shadi Aghamohammad
Amin Sepehr
Seyedeh Tina Miri
Saeideh Najafi
Mohammad R. Pourshafie
Mahdi Rohani
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04153-y

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Research

Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response

Retraction Note

Retraction Note: Polyphenols from Conyza dioscoridis (L.) ameliorate Alzheimer’s disease- like alterations through multi-targeting activities in two animal models

Research

Effects of probiotics on pancreatic inflammation and intestinal integrity in mice with acute pancreatitis

Research

Gallic acid rescues uranyl acetate induced-hepatic dysfunction in rats by its antioxidant and cytoprotective potentials

Research

Experience of parents in delivering pediatric tuina to children with symptoms of attention deficit hyperactivity disorder during the COVID-19 pandemic: qualitative findings from focus group interviews

Research

Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death